StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3057% above fair value
$251.41+0.62 (+0.25%)

Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –

Biogen operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Biogen's operating income for the twelve months ending Mar 31, 2022 was $2.48B, down 33.1% year over year. For fiscal 2021 it was $2.84B, down 37.6% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $7.04B in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2021Dec 31, 2021$2.84B-37.6%
FY2020Dec 31, 2020$4.55B-35.4%
FY2019Dec 31, 2019$7.04B+19.6%
FY2018Dec 31, 2018$5.89B+10.2%
FY2017Dec 31, 2017$5.35B+3.8%
FY2016Dec 31, 2016$5.15B+5.3%
FY2015Dec 31, 2015$4.89B+23.1%
FY2014Dec 31, 2014$3.97B+57.9%
FY2013Dec 31, 2013$2.52B+35.5%
FY2012Dec 31, 2012$1.86B+7.6%
FY2011Dec 31, 2011$1.72B+38.1%
FY2010Dec 31, 2010$1.25B-3.6%
FY2009Dec 31, 2009$1.30B+6.7%
FY2008Dec 31, 2008$1.21B+55.6%
FY2007Dec 31, 2007$779.77M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2022Mar 31, 2022$610.70M-37.3%
Q4 FY2021Dec 31, 2021$587.10M–
Q3 FY2021Sep 30, 2021$794.00M-26.9%
Q2 FY2021Jun 30, 2021$485.70M-75.4%
Q1 FY2021Mar 31, 2021$973.90M-46.5%
Q4 FY2020Dec 31, 2020-$330.60M-118.6%
Q3 FY2020Sep 30, 2020$1.09B-39.9%
Q2 FY2020Jun 30, 2020$1.97B+1.0%
Q1 FY2020Mar 31, 2020$1.82B+21.1%
Q4 FY2019Dec 31, 2019$1.78B+23.2%
Q3 FY2019Sep 30, 2019$1.81B+6.4%
Q2 FY2019Jun 30, 2019$1.96B+61.2%
Q1 FY2019Mar 31, 2019$1.50B-2.1%
Q4 FY2018Dec 31, 2018$1.44B-1.6%
Q3 FY2018Sep 30, 2018$1.70B+2.6%
Q2 FY2018Jun 30, 2018$1.21B+1.0%
Q1 FY2018Mar 31, 2018$1.53B+49.8%
Q4 FY2017Dec 31, 2017$1.47B+65.2%
Q3 FY2017Sep 30, 2017$1.65B–
Q2 FY2017Jun 30, 2017$1.20B–
Q1 FY2017Mar 31, 2017$1.02B–
Q4 FY2016Dec 31, 2016$887.50M–

More Biogen figures

See a number that looks wrong?